- Home
- FRBA vs DSGN Comparison
FRBA vs DSGN Comparison
Compare FRBA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- DSGN
- Stock Information
- Founded
- FRBA 2007
- DSGN 2017
- Country
- FRBA United States
- DSGN United States
- Employees
- FRBA N/A
- DSGN N/A
- Industry
- FRBA Major Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FRBA Finance
- DSGN Health Care
- Exchange
- FRBA Nasdaq
- DSGN Nasdaq
- Market Cap
- FRBA 377.6M
- DSGN 430.6M
- IPO Year
- FRBA N/A
- DSGN 2021
- Fundamental
- Price
- FRBA $15.80
- DSGN $7.45
- Analyst Decision
- FRBA Strong Buy
- DSGN Hold
- Analyst Count
- FRBA 1
- DSGN 1
- Target Price
- FRBA $19.00
- DSGN $6.00
- AVG Volume (30 Days)
- FRBA 38.9K
- DSGN 338.7K
- Earning Date
- FRBA 10-22-2025
- DSGN 11-05-2025
- Dividend Yield
- FRBA 1.52%
- DSGN N/A
- EPS Growth
- FRBA 3.77
- DSGN N/A
- EPS
- FRBA 1.65
- DSGN N/A
- Revenue
- FRBA $135,175,000.00
- DSGN N/A
- Revenue This Year
- FRBA $15.53
- DSGN N/A
- Revenue Next Year
- FRBA $5.97
- DSGN N/A
- P/E Ratio
- FRBA $9.55
- DSGN N/A
- Revenue Growth
- FRBA 9.51
- DSGN N/A
- 52 Week Low
- FRBA $12.74
- DSGN $2.60
- 52 Week High
- FRBA $17.40
- DSGN $7.93
- Technical
- Relative Strength Index (RSI)
- FRBA 50.15
- DSGN 62.87
- Support Level
- FRBA $15.38
- DSGN $6.68
- Resistance Level
- FRBA $15.92
- DSGN $7.93
- Average True Range (ATR)
- FRBA 0.32
- DSGN 0.61
- MACD
- FRBA 0.04
- DSGN 0.14
- Stochastic Oscillator
- FRBA 53.75
- DSGN 87.39
About FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.